Advancing Respiratory Care with Dual-Action Therapy

Chronic obstructive pulmonary disease (COPD) remains a significant health challenge across India. Therefore, healthcare providers constantly seek more effective ways to manage chronic bronchitis and airway obstruction. Theon Pharmaceuticals recently achieved a major milestone by launching the Acebrophylline Erdosteine bi-layered tablet. This product represents the first formulation of its kind in India to receive a DCGI license. It specifically targets the unmet needs of patients requiring long-term respiratory support.

Benefits of the Acebrophylline Erdosteine Bi-layered Tablet

This innovative combination brings together two powerful molecules with complementary mechanisms. Acebrophylline functions as a bronchodilator and a mucoregulator. It effectively stimulates surfactant production and reduces bronchial hyper-responsiveness. Moreover, its anti-inflammatory properties help soothe irritated airways. Meanwhile, Erdosteine acts as a potent mucolytic agent. It breaks disulfide bonds in mucus to reduce viscosity and facilitate clearance. Consequently, this dual approach ensures comprehensive support for pulmonary function. Additionally, Erdosteine provides antioxidant protection against oxidative stress, which is vital for chronic therapy.

Superiority Over Conventional Combinations

Clinical evidence suggests that this combination offers significant advantages over older therapies like Acebrophylline and Acetylcysteine. Specifically, Erdosteine shows a superior ability to reduce COPD exacerbations and hospitalizations. Furthermore, the patented bi-layered technology optimizes the release kinetics of both drugs. This design ensures better therapeutic outcomes and enhances patient compliance. Therefore, clinicians can provide a safer and more tolerable alternative for long-term respiratory management. The formulation also reduces the need for rescue medications, improving the overall quality of life for patients.

Frequently Asked Questions

Q1: What are the primary indications for this bi-layered tablet?

This tablet treats chronic bronchitis in patients with COPD. It helps manage long-term symptoms by improving mucus clearance and reducing airway inflammation.

Q2: How does the bi-layered technology benefit the patient?

The patented bi-layered design ensures the optimized release of Acebrophylline and Erdosteine. This leads to more stable drug levels, improved efficacy, and better stability of the formulation.

Q3: Is this combination suitable for long-term use?

Yes, the Acebrophylline and Erdosteine combination is positioned as a safe and well-tolerated option for chronic therapy. It offers a balanced approach to efficacy and safety in COPD management.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Theon Pharma Launches Bi-Layered Acebrophylline–Erdosteine Platform for Respiratory Care - ETHealthworld


2. Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2007.


3. Dal Negro RW, et al. Erdosteine reduces the risk of hospitalizations and costs in COPD: a post-hoc analysis of the RESTORE study. Multidiscip Respir Med. 2019.